Neuroblastoma Market Size, Global Trends, Business Analysis and Forecast to 2023
Neuroblastoma Market –
Overview:
Neuroblastoma cases have
increased significantly due to a range of factors from genetic to environmental
factors. Reports that gauge the healthcare industry have been made available by
Market Research Future which creates reports on several industry verticals that
review the market growth and prospects. The market is projected to reach a CAGR
of 3.7 % in the course of the forecast period.
Increased detection of cases
related to neuroblastoma is primarily due to better detection methods and
genetic predisposition to the disease. The Neuroblastoma
Market Size is expected to gather traction primarily due to research
being conducted to treat the disease as well as better detection and treatment
methods. Moreover, better knowledge of symptoms and diagnostic equipment is
expected to motivate the market in the coming period.
According to the American
Society of Clinical Oncology (ASCO) April 2018 publication, every year, more
than 700 children get diagnosed with neuroblastoma in the US and it is also
indicated that neuroblastoma is the most common cancer in children younger than
1 year. It is more commonly found in boys compare to girls. The increasing
cases of childhood cancer boost market growth during the forecast period.
Competitive Analysis:
The improvements in various
domestic economies are expected to motivate the development of the market in
the upcoming period. The accessibility to key tactical opportunities leading to
consequent stabilization of inflation is anticipated to create promising
openings for expansion in the coming years. In the coming years, the influence
exerted by relatively high-income levels in nations around the world and the
potential gains observed to some of the currencies in the world is expected to
reinforce the evolution of the market in the forecast period. The progress of
the market is expected to capture increased momentum in the coming years
primarily due to the presence of conducive government policies. The growth
turnaround in the market is expected to activate new opportunities for
expansion of the market. A considerable rise in the number of investors in the
market is projected to create an advantageous scenario for the progress of the
market in the forecast period.
Major Players:
·
APEIRON Biologics AG
·
LUMITOS AG
·
NANTGE Healthcare
·
Pfizer Inc
·
United Therapeutics Corp
·
GL Pharm Tech Corporation
·
RxStrategies
·
Aetna Inc
Segmental Analysis:
·
The segmentation of the neuroblastoma market
has been conducted on the basis of treatment, diagnostics, and end user.
·
Based on diagnostics, the neuroblastoma
market has been segmented into MIBG scan, various tests, imaging, and biopsy.
·
On the basis of treatment, the neuroblastoma
market has been segmented into surgery, chemotherapy, stem cell transplant,
radiation therapy, immunotherapy, and monoclonal antibody treatment.
·
The end user segmentation of the
neuroblastoma market comprises of research centers, hospitals, ambulatory
surgical centers, diagnostic centers, and others.
·
The neuroblastoma market has been segmented
on the basis of region, comprises of Asia Pacific, the Americas, Europe, the
Middle East, and Africa.
Detailed Regional
Analysis:
Geographically, the Americas is expected to dominate
the global neuroblastoma market owing to the presence of well-developed
healthcare sector, rising prevalence of infant cancer cases, and growing
expenditure for the healthcare sector. Europe is expected to hold the second
largest position in the global neuroblastoma market owing to the growing number
of child healthcare centers for cancer treatment and raising awareness about
the treatment for neuroblastoma.
According to the Cancer Research UK May 2018 publication, around 100
infants are detected with neuroblastoma every year in the UK. This provides
favorable backgrounds for the neuroblastoma market to grow.
Asia-Pacific is expected to be the fastest
growing market owing to the increasing children cancer base and increasing
developments in the healthcare segment
According to the Neuroblastoma Australia
organization October 2018 article, every year approximately 40 cases of
neuroblastoma are indicated in Australia due to some unknown genetic problems
which will support the market growth.
Comments
Post a Comment